Brand Name :
effient
Synonyms :
prasugrel
Class :
Antiplatelet agent, hematologic
Dosage Forms & Strengths
Tablet
5mg
10mg
Initial dose
:
60
mg
Orally
once a day
Tablet
Maintenance dose: 10mg/day orally combined with 81-325mg/day aspirin
Acute Coronary Syndrome
<75 years:
Loading dose: 60mg orally
Maintenance dose: 10mg/day orally combined with 81-325mg/day aspirin
>75 years:
Not recommended due to intracranial bleeding
may increase the toxic effect of anti-platelet agents
may increase the toxic effect of anti-platelet agents
may increase the anti-coagulant effect of anti-platelet agents
may reduce the serum concentration of anti-platelet agents
may increase the toxic effect of anti-platelet agents
may increase the toxic effect of anti-platelet agents
The inhibition of gastrointestinal (GI) absorption by codeine leads to a decrease in the level or effectiveness of prasugrel
When both drugs are combined, there may be an increased risk of bleeding and fatal hemorrhage
may increase the anti-platelet effect
may increase the anti-platelet effect
may increase the anti-platelet effect
may increase the anti-platelet effect
may increase the anti-platelet effect
may increase the anti-platelet effect
It may enhance the risk of bleeding by affecting coagulation when combined with omega-3 carboxylic acids
may enhance the effects by pharmacodynamic synergism when combined with prasugrel
telotristat ethyl: they may diminish serum concentrations of prasugrel
Frequency defined:
1-10%
Hypercholesterolemia/hyperlipidemia
Back pain
Nausea
Cough
Fatigue
Atrial fibrillation
Leukopenia
Pyrexia
Pain in extremity
Hypertension
Headache
Dyspnea
Dizziness
Hypotension
Noncardiac arrest
Bradycardia
Rash
Peripheral edema
Diarrhea
<1%
Abnormal hepatic function
Hematoma
Hemorrhage
Angioedema
Hemolysis
Abnormal liver function
Post-marketing reports
Hypersensitivity reactions: anaphylaxis
Thrombocytopenia
Pregnancy consideration:
US FDA category: C
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: prasugrel
Pronounced: [ PRA-soo-grel ]
Why do we use prasugrel?
It is used to prevent heart attacks, strokes, and other severe issues with your heart and blood vessels